193P Translational, PK, PD, and immunophenotyping analyses of tuvusertib + niraparib in a phase Ib open-label multicenter dose-escalation study in patients with advanced solid tumo... von Tolcher, A.W., Yap, T.A., Plummer, R., Sommerhalder, D., Rodon, J., Lagonera, M., Bergmann, P., Perez, V. Sanchez, Wohlfeil, N., Wang, D., Mukker, J. Kaur, Sessa, G., Manginelli, A., de Bono, J.S.

Volltext

EP.12H.09 Phase 1b/2a Study of ATR Inhibitor Tuvusertib + Anti-PD-1 Cemiplimab in Patients with Advanced Non-Squamous NSCLC von Vokes, N., Paz-Ares, L., Cappuzzo, F., Yamamoto, N., Gray, J.E., Owonikoko, T., Ariyasu, R., Ishii, H., Kang, J.H., Lee, S.-H., Hallwachs, R., Coenen-Stass, A., Sarholz, B., Pudelko, L., Kaur Mukker, J., Moulin, C., Gounaris, I., Villaruz, L.C.

Volltext